
Drugs in R&D, an international, Medline-Indexed, peer reviewed, #OpenAccess, online journal, focusing on #pharmacology
New Zealand
Joined June 2010
- Tweets127
- Following145
- Followers82
- Likes5
Not many new antifungals approved in the last number of years. This nice PK review of First-in-Class Ibrexafungerp was recently published in Drugs in R&D link.springer.com/article/10…
1
The political theatre of the UK's travel ban on South Africa thelancet.com/journals/lance…
Knowledge of DDI with voriconazole in hematopoietic stem cell transplantation is crucial. Read about it here: link.springer.com/article/10… #openaccess #voriconazole
Research shows safety of agalsidase alfa in patients with Fabry Disease
link.springer.com/article/10…
#fabrydisease, #agalsidase
Drugs in R&D retweeted
We're celebrating the 50th birthday of our flagship Adis Premier journal @DrugsJournal (I.F. 9.546)! Publishing definitive #research and #reviews for healthcare professionals; plain language summaries and digital features are now available to maximise readership engagement.
What to do with immunosuppressive medications when receiving COVID vaccines. Check out this Current Opinion just published: link.springer.com/article/10… #COVID19 #vaccine
1
This article has been making an impact with plenty citations since publication:
Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells #SARSCoV2 #peptide
rdcu.be/ck0Pw
Our latest publication:
Population Pharmacokinetic Analysis of Rivipansel in Healthy Subjects and Subjects with Sickle Cell Disease #sickleCell #rivipansel
rdcu.be/ck0Pr
Dosing considerations for Antibodies against COVID-19
rdcu.be/cgxOh #COVID19
Great review just published on repurposed COVID-19 Medications: rdcu.be/cgxN8 #COVID
Identifcation of a Potential Peptide Inhibitor of SARS‑CoV‑2 Targeting its Entry into the Host Cells
link.springer.com/article/10…
#SARSCoV2
Our latest review article looks at re-purposing of fingolimod for other neurologic disorders
#fingolimid #neurology
link.springer.com/content/pd…
Drugs in R&D retweeted
Exciting #news for Oncology and Therapy...
The journal is now indexed on #PubMed
All articles from and including June 2018 are now indexed on the site: buff.ly/2OS26lA
#cancer #oncology #openaccess
Our latest Review Article: Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor: link.springer.com/content/pd… #tenosynovial #pexidartinib
Malaria continues to be a public health concern. This nice study from Mali shows ex-vivo sensitivity of Plasmodium falciparum to common anti-malarial drugs.
rdcu.be/b457a
In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection
rdcu.be/b4Zi0
Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers
rdcu.be/b4ZhQ
Rational use of hydroxychloroquine in COVID-19, based on existing Pharmacokinetic data
rdcu.be/b3EEW
Another interesting article on this controversial topic:
Extrapolation of Drug Clearance in Children ≤2 Years of Age
from Empirical Models Using Data from Children (>2 Years) and Adults
link.springer.com/content/pd…


